BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma (BEAT-meso)

April 22, 2024 updated by: ETOP IBCSG Partners Foundation

A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma

The aim of this clinical trial is to assess the effect of treatment with a monoclonal antibody called atezolizumab in patients diagnosed with a type of lung cancer called malignant pleural mesothelioma. The efficacy (whether the treatment works), safety and tolerability (side effects of treatment) of atezolizumab plus bevacizumab in combination with standard chemotherapy versus bevacizumab in combination with standard chemotherapy will be investigated.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer arising from the mesothelial surface of the pleura. In Europe, the incidence is about 20 per million and is almost always caused by asbestos exposure, with a usual lag time of 30 years between exposure and presentation. Patients diagnosed with advanced MPM have limited treatment options, representing a strict unmet need. Despite decades of clinical research, cytotoxic chemotherapy remains one of the few therapeutic options that has been proven to improve survival in advanced MPM in a randomised controlled trial.

The combination of cisplatin and pemetrexed has become standard first-line therapy worldwide for patients who are not suitable for aggressive surgery or in whom chemotherapy is recommended as part of a multimodality regimen. Carboplatin is often substituted for cisplatin, due to simpler and shorter administration and assumption of a more favourable toxicity profile based on experience in other diseases. Patients with MPM have limited treatment options, representing a strict unmet need.

An antibody is a common type of protein usually made in the body in response to a foreign substance. Antibodies attack foreign substances and protect against infection. The two monoclonal antibodies (atezolizumab and bevacizumab) used in this trial are laboratory-produced antibodies. Atezolizumab is engineered to attach to immune cells to stimulate their activity against cancer cells.

Atezolizumab and bevacizumab are both approved by the European Medicines Agency for the treatment of lung and other cancers. The addition of atezolizumab to bevacizumab plus standard chemotherapy for the treatment of MPM is being investigated in this trial.

All participants will receive 4-6 cycles of standard chemotherapy consisting of carboplatin AUC 5 (area under the plasma concentration versus time curve) plus pemetrexed 500mg/m^2 given intravenously, on day 1 of every 3 week cycle for about 12 to 18 weeks.

Participants will be randomly assigned to one of two treatment groups:

Treatment 1

  • Bevacizumab 15 mg/kg intravenously on day 1 of every 3-week cycle, plus
  • 4-6 cycles of chemotherapy

OR

Treatment 2

  • Atezolizumab 1200 mg fixed dose intravenously on day 1 of every 3-week cycle, plus
  • Bevacizumab 15 mg/kg, intravenously on day 1 of every 3-week cycle, plus
  • 4-6 cycles of chemotherapy

Participants will continue to receive treatment until disease progression, or until treatment is stopped at the request of the participant or treating doctor, or the participant withdraws consent.

A total of 400 participants from approximately 45 centres in Europe are expected to be included in this trial which will take approximately 6 years to be completed after the first participant is enrolled.

Study Type

Interventional

Enrollment (Actual)

401

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Belgium
      • Leuven, Belgium
        • University Hospital Leuven
      • Liege, Belgium
        • CHU Liege
  • France
      • Bordeaux, France
        • Unicancer - Institut Bergonie
      • Caen, France
        • Caen- CHU
      • Le Mans, France
        • Le Mans - CHG
      • Lyon, France
        • Lyon - Centre Léon Bérard
      • Marseille, France
        • Hospital Nord
      • Paris, France
        • Curie Cancer Center Paris
      • Toulouse, France
        • Toulouse - CHU
      • Tours, France
        • Tours - CHU
  • Italy
      • Alessandria, Italy
        • SS Antonio e Biagio e Cesare Arrigo Hospital
      • Bari, Italy
        • IRCCS Instituto Tumori Giovanni Paolo II
      • Milan, Italy
        • Fondazione IRCCS Istituto Nazionale die Tumori
      • Milan, Italy
        • Instituto Europeo di Oncologia (IEO)
      • Treviso, Italy
        • AULSS2 Marca Trevigiana Treviso
      • Turin, Italy
        • University Hospital of Turin
  • Spain
      • Alicante, Spain
        • Alicante University Hospital ISABIAL
      • Barcelona, Spain
        • ICO Hospitalet
      • Barcelona, Spain
        • Vall Hebron University Hospital/Vall Hebron Institue Oncology
      • Majadahonda, Spain
        • Puerta de Hierro Hospital
      • Sabadell, Spain
        • Hospital Parc Tauli Sabadell
      • Seville, Spain
        • Virgen del Rocio
      • Vigo, Spain
        • Complexo Hospitalario Universitario de Vigo
  • Switzerland
      • Aarau, Switzerland
        • Kantonsspital Aarau
      • Bellinzona, Switzerland
        • Istituto Oncologica della Svizzera Italiana
      • Bern, Switzerland
        • Ferdinando Cerciello
      • Chur, Switzerland
        • Kantonsspital Graubünden
      • Lausanne, Switzerland
        • CHUV
      • Lucerne, Switzerland
        • Luzerner Kantonsspital
      • Saint Gallen, Switzerland
        • Kantonsspital St. Gallen
      • Winterthur, Switzerland
        • Kantonsspital Winterthur
      • Zürich, Switzerland
        • UniversitätSpital Zürich
  • United Kingdom
      • Cambridge, United Kingdom
        • Addenbrooke's Hospital
      • Liverpool, United Kingdom
        • Clatterbridge Cancer Centre
      • London, United Kingdom
        • Guy's and St Thomas' Hospital
      • London, United Kingdom
        • Royal Marsden Hospital (Fulham Road)
      • London, United Kingdom
        • Royal Marsden Hospital (Sutton)
      • Maidstone, United Kingdom
        • Kent Oncology Centre
      • Manchester, United Kingdom
        • Wythenshawe Hospital
      • Plymouth, United Kingdom
        • Plymouth Hospitals Nhs Trust
      • Sheffield, United Kingdom
        • Weston Park Hospital
      • Truro, United Kingdom
        • Royal Cornwall Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Histologically confirmed advanced malignant pleural mesothelioma (all histological subtypes are eligible)
  • Not amenable for radical surgery based on local standards
  • Evaluable disease or measurable disease as assessed according to the modified response evaluation criteria for solid tumours for mesothelioma (mRECIST) v1.1
  • Availability of tumour tissue for translational research
  • Age >18 years
  • Performance Status 0-1
  • Life expectancy >3 months
  • Adequate haematological, renal and liver function
  • Completed baseline quality of life (QoL) questionnaire
  • Women of childbearing potential and sexually active men must agree to use highly effective contraception
  • Able to understand and give written informed consent and comply with trial procedures

Exclusion Criteria:

  • Prior treatment for malignant pleural mesothelioma. Prior radiotherapy for symptom control is allowed, but the irradiated lesion cannot be used as target lesion. If the patient has another target lesion, the patient is eligible.
  • Treatment with systemic immune-stimulatory agents within 4 weeks or five half-lives of the drug prior to randomisation and during protocol treatment.
  • Treatment with systemic immunosuppressive medications within 2 weeks prior to randomisation and during protocol treatment.
  • Previous allogeneic tissue/solid organ transplant
  • Live vaccines within 4 weeks prior to first dose of protocol treatment
  • Inadequately controlled hypertension
  • Prior history of hypertensive crisis or hypertensive encephalopathy
  • Significant vascular disease within 6 months prior to randomisation
  • History of haemoptysis
  • Evidence of bleeding diathesis or coagulopathy
  • Active autoimmune disease that has required systemic treatment in past 2 years
  • History of active diverticulitis
  • Previous treatment with atezolizumab and/or bevacizumab or parallel participation in other interventional clinical trial with atezolizumab and/or bevacizumab.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Bevacizumab plus chemotherapy
Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m^2 intravenously on day 1 every 3 weeks
Drug: Carboplatin
Carboplatin belongs to the group of medicines known as alkylating agents. Carboplatin interferes with the growth of cancer cells, which eventually are destroyed.
Other Names:
  • Carboplatin Accord
Drug: Pemetrexed
Pemetrexed is a type of drug known as an anti metabolite. It stops cells making and repairing DNA so they can't grow and multiply.
Other Names:
  • Alimta
Drug: Bevacizumab
Bevacizumab is an angiogenesis inhibitor. It works by targeting a protein called vascular endothelial growth factor (VEGF) that helps cancers form new blood vessels. By stopping this process, bevacizumab 'suffocates' the blood supply to the cancer, shrinking it and stopping it from growing.
Other Names:
  • Avastin
Experimental: Atezolizumab plus bevacizumab plus chemotherapy
Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m^2 intravenously on day 1 every 3 weeks
Drug: Carboplatin
Carboplatin belongs to the group of medicines known as alkylating agents. Carboplatin interferes with the growth of cancer cells, which eventually are destroyed.
Other Names:
  • Carboplatin Accord
Drug: Pemetrexed
Pemetrexed is a type of drug known as an anti metabolite. It stops cells making and repairing DNA so they can't grow and multiply.
Other Names:
  • Alimta
Drug: Bevacizumab
Bevacizumab is an angiogenesis inhibitor. It works by targeting a protein called vascular endothelial growth factor (VEGF) that helps cancers form new blood vessels. By stopping this process, bevacizumab 'suffocates' the blood supply to the cancer, shrinking it and stopping it from growing.
Other Names:
  • Avastin
Drug: Atezolizumab
Atezolizumab is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain protein in cancer cells. This helps the immune system to fight against the cancer cells, and helps to slow tumor growth.
Other Names:
  • Tecentriq
  • RO5541267

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall Survival (OS)
Time Frame: From date of randomisation until death from any cause, assessed up to 58 months
Overall survival is defined as the time from the date of randomisation until death from any cause. Data for patients who are not reported as having died at the date of analysis will be censored at the date when they were last known to be alive. Data for patients without post-baseline information will be censored at the date of randomization (plus 1 day).
From date of randomisation until death from any cause, assessed up to 58 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Progression-free Survival (PFS) according to the mRECIST v1.1
Time Frame: From date of randomisation until documented progression or death, if progression is not documented, assessed up to 58 months
PFS is defined as the time from the date of randomisation until documented progression (according to the mRECIST v1.1) or death, if progression is not documented. Censoring (for participants without a PFS/death event) will occur at the date of last tumour assessment. Patients without a post-baseline tumour assessment will be censored at the date of randomization (plus 1 day).
From date of randomisation until documented progression or death, if progression is not documented, assessed up to 58 months
Objective Response Rate (ORR)
Time Frame: From start of protocol treatment acorss all time-points until end of protocol treatment or, as an alternative approach, until the end of follow-up, assessed up to 58 months
Defined as the percentage of patients that achieve a best overall response [complete response (CR) or partial response (PR)] evaluated according to the mRECIST v1.1 across all post-randomization time-points until the end of protocol treatment or, as an alternative approach, until the end of follow-up. Confirmation of response will not be required.
From start of protocol treatment acorss all time-points until end of protocol treatment or, as an alternative approach, until the end of follow-up, assessed up to 58 months
Disease Control (DC) at 24 weeks
Time Frame: 24 weeks after protocol treatment start
Defined as complete or partial response, or disease stabilisation at 24 weeks.
24 weeks after protocol treatment start
Time to Treatment Failure (TTF)
Time Frame: From randomisation until discontinuation of protocol treatment for any reason, assessed up to 58 months
Defined as the time from the date of randomisation to discontinuation of protocol treatment for any reason (including progression of disease, death, discontinuation of at least one of the drugs consisting the treatment combination due to any reason, such as toxicity or refusal). Censoring will occur at the last follow-up date.
From randomisation until discontinuation of protocol treatment for any reason, assessed up to 58 months
Duration of Response (DoR)
Time Frame: From date of first documentation of objective response until date of first documented progression/ relapse or death, assessed up to 58 months
Defined as the interval from the date of first documentation of objective response (complete response or partial response, according to the mRECIST v1.1) to the date of first documented progression/ relapse or death.
From date of first documentation of objective response until date of first documented progression/ relapse or death, assessed up to 58 months
Number of participants with treatment related adverse events according to Common Toxicity Criteria for Adverse Events (CTCAE) v5.0
Time Frame: Assessed from the date of informed consent until 90 days after protocol treatment discontinuation. Analysed at 58 months after randomisation of the first patient
Assessed through analysis of the worst grade of toxicity/adverse events and will include all participants who received at least one dose of protocol treatment. Adverse events leading to dose interruption, withdrawal of protocol treatment and deaths, laboratory parameters and abnormalities and vital signs over the whole treatment period will be assessed and graded according to CTCAE v5.0 criteria.
Assessed from the date of informed consent until 90 days after protocol treatment discontinuation. Analysed at 58 months after randomisation of the first patient

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

ETOP IBCSG Partners Foundation

Collaborators

Hoffmann-La Roche

Investigators

  • Study Chair: Enriqueta Felip, MD-PhD, Vall d'Hebron University Hospital
  • Study Chair: Sanjay Popat, PhD, MBBS, Royal Marsden NHS Foundation Trust

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 30, 2019

Primary Completion (Estimated)

June 1, 2024

Study Completion (Estimated)

June 1, 2024

Study Registration Dates

First Submitted

November 20, 2018

First Submitted That Met QC Criteria

November 30, 2018

First Posted (Actual)

December 3, 2018

Study Record Updates

Last Update Posted (Actual)

April 23, 2024

Last Update Submitted That Met QC Criteria

April 22, 2024

Last Verified

April 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ETOP 13-18
  • 2018-002180-25 (EudraCT Number)
  • MO40388 (Other Identifier: F.Hoffman-La Roche Ltd)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pleural Mesothelioma Malignant Advanced

Clinical Trials on Carboplatin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe